Načítá se...
Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces.
Ceftazidime was used as the only intravenous agent for treating lower respiratory tract infections in patients with cystic fibrosis. The risks of inducing beta lactamases and conferring antibiotic resistance are high when monotherapy is used; so the emergence of resistant bacteria was studied prospe...
Uloženo v:
| Vydáno v: | Thorax |
|---|---|
| Hlavní autoři: | , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
1991
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC463083/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/1903896/ https://ncbi.nlm.nih.govhttps://doi.org/10.1136/thx.46.4.239 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|